Citi analyst Neena Bitritto-Garg says incremental updates on Roivant Sciences’ fiscal Q4 earnings call included continued positive progress on the Vtama launch, particularly on reimbursement. Brepocitinib’s Phase 2b data in systemic lupus erythematosus in Q4 “still remains more under the radar” and represents a “free call on shares,” the analyst tells investors in a research note. Citi remains a buyer of Roivant shares given potential upside from upcoming events and the recent weakness on insider sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- UPDATE — Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- Roivant Sciences expects cash to fund operations into 2H25
- Roivant Sciences announces upcoming milestones
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- Roivant Sciences reports Q4 EPS from cont. ops. (20c), consensus (36c)